The Cigna Group
CI
$286.69
+0.50%
The Cigna Group is a major integrated healthcare services company operating in the Medical - Healthcare Plans industry, providing pharmacy benefit management (PBM) and health insurance services. It is a dominant player in the PBM space, a position solidified by its 2018 merger with Express Scripts, and serves a significant base of employer-sponsored health plans and government contracts. The current investor narrative is focused on the company's strategic pivot, as it recently raised its financial outlook while announcing the exit from the individual exchange business and a strategic review of its eviCore unit, signaling a sharper focus on its core PBM and employer-focused insurance operations amid a backdrop of strong quarterly performance.…
CI
The Cigna Group
$286.69
Related headlines
Investment Opinion: Should I buy CI Today?
Rating & Thesis: Hold. Cigna presents a classic value trap scenario—deeply undervalued on paper but lacking a clear near-term catalyst to reverse its severe negative momentum and address margin concerns. The analyst consensus, while limited, shows a tight revenue range but does not provide a strong counter-narrative to the market's skepticism.
Supporting Evidence: The valuation is compelling: a forward P/E of 8.50x and a P/S of 0.27x are far below industry averages, suggesting massive pessimism is priced in. Fundamentally, the company is not broken, with 10.39% YoY revenue growth in Q4 2025 and robust TTM free cash flow of $8.39 billion. The return on equity of 14.28% indicates decent capital efficiency. However, the 1-year price decline of -7.64% and drastic underperformance versus the market overshadow these metrics.
Risks & Conditions: The two biggest risks are persistent margin compression and failed execution of the strategic pivot. This Hold rating would upgrade to a Buy if the stock demonstrates sustained quarterly gross margin recovery above 9% or breaks above key technical resistance near $300 on high volume, signaling a momentum shift. It would downgrade to a Sell if revenue growth decelerates below 5% YoY or if the price breaks below the 52-week low of $239.51. The stock is undervalued relative to its history and peers, but fairly valued given the current execution and sentiment risks.
Sign up to view all
CI 12-Month Price Forecast
Cigna is a fundamentally sound company trapped in a negative sentiment cycle. Its valuation is undeniably cheap, and its cash generation is strong, but the market is penalizing it for margin volatility and strategic uncertainty. The base case of range-bound trading is most likely, as the company works through its pivot. The stance would upgrade to bullish on clear evidence of margin stabilization and a technical breakout above $300. It would turn bearish if the stock breaks below $260, signaling a failure of the value support level.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on The Cigna Group's 12-month outlook, with a consensus price target around $372.70 and implied upside of +30.0% versus the current price.
Average Target
$372.70
7 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
7
covering this stock
Price Range
$229 - $373
Analyst target range
Analyst coverage for Cigna is limited, with only 7 analysts providing estimates, which suggests this large-cap stock may have less institutional research focus than peers, potentially leading to higher volatility in sentiment. The average revenue estimate for the period is $338.05 billion, with a range from $329.56 billion to $346.61 billion; this relatively tight 5% spread between the low and high targets indicates a fair degree of consensus on the company's near-term revenue trajectory, though the limited number of analysts tempers the strength of this signal.
Bulls vs Bears: CI Investment Factors
The bull case for Cigna is anchored in its deep valuation discount, strong cash generation, and strategic refocusing on its core PBM strengths. The bear case is driven by severe market underperformance, recent margin compression, and the risks inherent in its strategic pivot. Currently, the bearish evidence appears stronger, as the stock's persistent negative momentum and significant underperformance reflect market skepticism that outweighs the attractive valuation metrics. The single most important tension in the investment debate is whether the company's strategic simplification and cost management can sustainably improve profitability (validating the low multiples) or if margin pressure and execution challenges will persist, justifying the market's discount.
Bullish
- Deep Valuation Discount: Cigna trades at a trailing P/E of 12.29x and a forward P/E of 8.50x, significantly below typical healthcare plan multiples in the mid-teens. Its Price-to-Sales ratio of 0.27x is exceptionally low, suggesting the market is pricing in minimal growth or significant risks, creating a potential value opportunity if fundamentals stabilize.
- Robust Cash Generation: The company generates substantial free cash flow, with $8.39 billion over the trailing twelve months. This strong cash flow supports a manageable debt-to-equity ratio of 0.75 and funds shareholder returns, providing financial stability and flexibility for strategic pivots.
- Strategic Focus on Core Strengths: Recent news confirms Cigna is exiting the individual exchange business and reviewing its eviCore unit, sharpening its focus on the dominant PBM and employer-focused insurance operations. This strategic simplification, coupled with a raised financial outlook, could improve operational efficiency and investor sentiment.
- Solid Revenue Growth Trajectory: Q4 2025 revenue of $72.47 billion grew 10.39% year-over-year, and sequential quarterly revenue increased from $65.50 billion in Q1 to the Q4 peak. This consistent top-line expansion demonstrates underlying business momentum despite margin pressures.
Bearish
- Severe Relative Underperformance: CI has underperformed the S&P 500 by 32.83% over the past year, with a 1-year price change of -7.64%. Trading at just 46% of its 52-week range ($239.51 to $338.89), the stock shows persistent negative momentum and a lack of market confidence, suggesting deep-seated concerns beyond valuation.
- Recent Margin Compression: Q4 2025 gross margin of 7.66% was notably lower than the trailing twelve-month figure of 9.45%, and net income declined from $1.87 billion in Q3 to $1.23 billion. This quarterly volatility and margin pressure raise questions about the sustainability of profitability amid the strategic pivot.
- Limited Analyst Coverage & Sentiment: Only 7 analysts provide estimates for this large-cap stock, indicating lower institutional research focus which can lead to sentiment volatility. While revenue estimates show a tight 5% range, the lack of broader coverage may reflect skepticism or complexity in the investment story.
- Execution Risk in Strategic Pivot: The exit from the individual exchange business and review of eviCore, while potentially positive long-term, introduce near-term execution and integration risks. Any missteps in this transition could further pressure margins and delay the realization of strategic benefits.
CI Technical Analysis
The stock is in a volatile, range-bound consolidation phase, with a 1-year price change of -7.64% significantly underperforming the broader market. As of the latest close at $285.27, the price sits at approximately 46% of its 52-week range ($239.51 to $338.89), indicating it is trading much closer to its annual low than its high, which may suggest a value opportunity but also reflects persistent negative momentum relative to the S&P 500. Recent short-term momentum shows a modest 1-month gain of 6.19%, which contrasts sharply with the negative 1-year trend; however, this recent strength is overshadowed by a 3-month decline of -2.12%, indicating the bounce lacks conviction and the stock continues to struggle for sustained upward traction. Key technical support is at the 52-week low of $239.51, while resistance looms at the 52-week high of $338.89; a sustained break above the recent high near $300 could signal a reversal, but the stock's low beta of 0.313 indicates it is significantly less volatile than the market, which historically suggests muted price swings but has not prevented a substantial 32.83% underperformance versus the SPY over the past year.
Beta
0.31
0.31x market volatility
Max Drawdown
-28.1%
Largest decline past year
52-Week Range
$240-$339
Price range past year
Annual Return
-10.7%
Cumulative gain past year
| Period | CI Return | S&P 500 |
|---|---|---|
| 1m | +2.9% | +4.0% |
| 3m | -1.4% | +8.2% |
| 6m | +5.4% | +11.5% |
| 1y | -10.7% | +24.3% |
| ytd | +2.7% | +8.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CI Fundamental Analysis
Cigna's revenue trajectory shows solid growth, with Q4 2025 revenue of $72.47 billion representing a 10.39% year-over-year increase, and sequential quarterly revenue has grown from $65.50 billion in Q1 to the Q4 peak, indicating a steady expansion. The company is profitable, posting Q4 2025 net income of $1.23 billion, though this represents a decline from the $1.87 billion in Q3, and the quarterly gross margin of 7.66% is notably lower than the 9.45% trailing twelve-month figure, pointing to potential margin compression in the most recent period. The balance sheet and cash flow position is robust, with a manageable debt-to-equity ratio of 0.75, strong trailing twelve-month free cash flow of $8.39 billion, and a return on equity of 14.28%, indicating the company generates ample cash to fund operations and shareholder returns without excessive financial risk.
Quarterly Revenue
$72.5B
2025-12
Revenue YoY Growth
+0.10%
YoY Comparison
Gross Margin
+0.07%
Latest Quarter
Free Cash Flow
$8.4B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CI Overvalued?
Given the positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE is 12.29x, while the forward PE is 8.50x, with the lower forward multiple implying the market expects earnings growth. Compared to sector averages, Cigna trades at a significant discount; its trailing PE of 12.29x is well below typical healthcare plan multiples (often in the mid-teens), and its Price-to-Sales ratio of 0.27x is exceptionally low, indicating the market assigns a very modest sales multiple relative to peers. Historically, the stock's own trailing PE has ranged widely; the current 12.29x is below the 14.83x from Q4 2025 and near the lower end of its multi-year range, suggesting the stock is priced for modest expectations or fundamental concerns, rather than optimism.
PE
12.3x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -94x~33x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
8.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Cigna's primary financial risk is earnings volatility, as evidenced by the Q4 2025 net income declining 34% from the prior quarter to $1.23 billion. The quarterly gross margin compression from a TTM 9.45% to 7.66% indicates potential pressure on its core PBM and insurance pricing power. While the debt-to-equity ratio of 0.75 is manageable, the company's valuation is heavily dependent on its ability to stabilize and grow earnings to justify even its low forward P/E of 8.5x.
Market & Competitive Risks: The stock trades at a significant discount to sector peers (P/E of 12.29x vs. mid-teens), but this discount reflects market fears of structural headwinds in healthcare services, including regulatory scrutiny on PBMs and pricing pressure. With a beta of 0.313, the stock has low market correlation but has still suffered a 32.83% underperformance versus the SPY, indicating severe company-specific or sector-specific de-rating. The strategic pivot, while potentially positive, adds uncertainty and could lead to further multiple compression if execution falters.
Worst-Case Scenario: A worst-case scenario involves a failure of the strategic review to unlock value, combined with continued margin erosion and a loss of a major PBM contract (e.g., with the Department of Defense). This could trigger analyst downgrades and a re-test of the 52-week low of $239.51. From the current price of $285.27, this represents a realistic downside of approximately -16%. A more severe bear case, incorporating a sector-wide de-rating, could see the stock fall toward the -28.12% max drawdown level, implying a loss of roughly -25% to -30%.
FAQ
The key risks are, in order of severity: 1) Execution & Strategic Risk: The pivot away from non-core businesses (individual exchange, eviCore review) could disrupt operations or fail to create value. 2) Profitability Risk: Quarterly gross margin compression (7.66% in Q4 vs. 9.45% TTM) may continue, eroding earnings. 3) Sentiment & Momentum Risk: The stock's severe 32.83% underperformance versus the market could persist, keeping the valuation depressed regardless of fundamentals. 4) Regulatory & Competitive Risk: The core PBM business faces ongoing political scrutiny and pricing pressure from clients and competitors.
The 12-month forecast presents three scenarios. The Base Case (60% probability) sees the stock trading between $285 and $310, as it remains range-bound on its value metrics without a major catalyst. The Bull Case (25% probability) targets $330-$340, driven by successful strategic execution and multiple expansion. The Bear Case (15% probability) risks a fall to $240-$260, re-testing the 52-week low. The base case is most likely, anchored by the company's solid revenue growth (~10% YoY) and strong cash flow, but capped by persistent margin and sentiment challenges.
CI is significantly undervalued based on standard valuation metrics relative to its sector and its own cash-generating ability. Its trailing P/E of 12.29x and forward P/E of 8.50x are well below healthcare plan peers, and its Price-to-Sales of 0.27x is exceptionally low. The market is paying a deep discount, which implies expectations of stagnant growth, continued margin pressure, or operational missteps. The valuation suggests the stock is cheap, but fairly so until the company demonstrates an ability to reverse the negative trends driving the discount.
CI is a good buy for a specific type of investor: a patient value hunter comfortable with uncertainty. The stock trades at a deep discount with a forward P/E of 8.50x and a P/S of 0.27x, implying significant upside if sentiment improves. However, its 1-year underperformance of 32.83% versus the market and recent margin compression present substantial near-term risk. It is not suitable for short-term traders or those seeking stable growth. A good buy under the condition that the investor has a multi-year horizon and believes in management's ability to execute its strategic refocusing.
CI is unsuitable for short-term investment. Its low beta of 0.313 suggests muted daily volatility, but its persistent negative momentum and range-bound trading offer little opportunity for quick gains. It is a candidate for a long-term (3+ year) value investment, where an investor can wait for the strategic pivot to bear fruit and for the market to recognize the disconnect between its price and fundamental cash generation. The suggested minimum holding period is 18-24 months to allow for the execution of the corporate strategy and potential multiple re-rating.
